查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2115711

全球真實世界資料（RWD）市場：按組件、資料來源、部署模式、應用、治療領域及最終用戶分類－市場規模、產業趨勢、機會分析及2026-2035年預測

Global Real-World Data (RWD) Market By Component, Data Source, By Deployment Model, Application, Therapeutic Area, End User - Market Size, Industry Dynamics, Opportunity Analysis And Forecast For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

隨著製藥公司、醫療服務提供者、生物技術公司、研究機構和其他醫療保健相關人員日益認知到來自常規臨床實踐的證據的價值，全球真實世界資料（RWD）市場迅速擴張。該市場在2025年的價值約為19.2億美元，預計到2035年將達到73.1億美元，在2026年至2035年的預測期內，CAGR為14.30%。

推動市場擴張的最重要因素之一是全球向精準醫療的轉變。傳統治療策略通常基於廣泛的患者群體，而精準醫療目的是識別更適合個別患者的生物學、遺傳學、臨床和人口統計學特徵的療法和干預措施。真實世界資料可以為研究人員提供豐富的患者特徵、治療史、疾病進展、治療反應和臨床結果資訊。

顯著的市場趨勢

全球真實世界資料（RWD）市場競爭異常激烈，領先的醫療資訊、分析、技術和臨床研究公司紛紛參與其中。 IQVIA、Flatiron Health、Optum、Syneos Health 和 Oracle Cerner 等公司已在該市場佔據穩固地位。

IQVIA憑藉其廣泛的全球醫療資訊生態系統和先進的分析能力，在真實世界資料（RWD）市場中保持著尤為強大的地位。 Flatiron Health則以其對腫瘤學領域的專注，在RWD市場中確立了獨特的地位。

Optum憑藉其廣泛的醫療保健和保險公司生態系統，建立了另一項顯著的競爭優勢。 Syneos Health的獨特之處在於，它將真實世界證據（RWE）能力與在臨床研究和合約研究服務方面的豐富經驗相結合。 Oracle Cerner憑藉其在醫院和醫療保健資訊基礎設施領域的廣泛影響力，帶來了獨特的競爭優勢。

關鍵成長要素

臨床試驗成本不斷攀升和高失敗率是推動真實世界資料（RWD）市場成長的主要因素。製藥和生物技術公司在開發新療法時面臨著巨大的財務和營運挑戰，因為藥物發現、臨床前研究、臨床開發、監管申報和商業化等每個階段都需要大量投資。失敗的風險仍然很高，尤其是在臨床開發階段，試驗失敗可能導致數年研究成果付諸東流，並造成數億美元的開發成本浪費。因此，生命科學公司擴大利用真實世界資料來改善決策、降低可避免的開發風險並簡化其臨床研究流程。

新機會的趨勢

人工智慧和自然語言處理驅動的資料管理正成為真實世界資料（RWD）市場的重要成長機會。醫療機構、製藥公司、生技公司和研究機構會產生大量的結構化和非結構化資訊。雖然諸如實驗室數值、藥物代碼、診斷和治療記錄等結構化資料可以輕鬆匯入資料庫，但大量具有臨床價值的資訊仍隱藏在非結構化的醫生觀察、病理報告、出院小結、放射學報告和其他說明文件中。先進的人工智慧（AI）和自然語言處理（NLP）技術正被擴大應用於將這些複雜的說明資訊轉化為標準化且可分析的資料集。

最佳化障礙

資料隱私和監管責任是可能阻礙全球真實世界資料（RWD）市場成長的重大挑戰。電子健康記錄、保險理賠資料庫、病患登記、基因組資訊和其他醫療保健資料集的日益普及，為研究和分析創造了巨大的機會，但也增加了保護高度敏感病患資訊的複雜性。醫療保健資料可能包含極其敏感的臨床、人口統計、遺傳和治療相關資訊，這使得醫療機構特別容易遭受隱私洩露、未授權存取、不當的資料共用和違規行為的侵害。隨著用於研究和商業用途的醫療保健資訊量持續成長，維護健全的隱私控制和管治結構變得日益重要。

目錄

第1章 執行摘要

  • 全球真實世界資料（RWD）市場

第2章 調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 主要訊息
    • 次要訊息
  • 量化研究
    • 主要訊息
    • 二手資訊
  • 主要調查受訪者組成：依地區分類
  • 本研究的前提
  • 市場規模估算
  • 資料三角測量

第3章 全球真實世界資料（RWD）市場概述

  • 產業價值鏈分析
  • 產業展望
    • 全球真實世界資料（RWD）和真實世界證據（RWE）產業概覽
    • 真實世界資料/真實世界證據：監管決策、外部對照組以及對擴大適應症的隨機對照試驗的補充
    • 電子健康記錄互通性、令牌化、人工智慧賦能的基因組和臨床協作資料集以及注重隱私的收益化。
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 價格趨勢分析：依組件

第4章 全球真實世界資料（RWD）市場分析

  • 競爭儀錶板
    • 市場集中度
    • 企業市場占有率分析，2025年
    • 競爭對手分析與基準測試

第5章 全球真實世界資料（RWD）市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 依組件
      • 關鍵見解
        • 資料資產和資料庫
        • 分析與技術平台
        • 服務
        • 資料聚合服務
        • 資料管理和整合服務
        • RWE發電服務
        • 諮詢服務
        • 監管和市場准入支持
    • 依資料來源
      • 關鍵見解
        • 電子健康紀錄（EHR）
        • 保險索賠和索賠資料
        • 病人登記
        • Pharmacy Data
        • 基因組學和體學資料
        • 穿戴式裝置和遠端監測資料
        • 患者產生的健康資料
        • 測試資料
        • 影像資料
    • 依部署模式
      • 關鍵見解
        • 雲端
        • 現場
        • 混合
    • 依用途
      • 關鍵見解
        • 藥物開發與臨床研究
        • 藥物安全監測及藥物安全
        • 監理決策支持
        • 市場准入和贖回
        • 精準醫療
        • 臨床結果評估
        • 醫療服務和人口健康管理
        • 衛生經濟學與結果研究（HEOR）
    • 依治療區域
      • 關鍵見解
        • 腫瘤學
        • 循環系統
        • 神經病學
        • 免疫學
        • 罕見疾病
        • 代謝性疾病
        • 感染疾病
        • 呼吸系統疾病
        • 其他
    • 依最終用戶
      • 關鍵見解
        • 製藥公司
        • 生技公司
        • 受託研究機構（CRO）
        • 醫療服務提供方
        • 支付機構和保險機構
        • 政府和監管機構
        • 學術研究機構
    • 依地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 其他亞太國家
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • UAE
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章 北美市場分析

第7章 歐洲市場分析

第8章 亞太市場分析

第9章 中東和非洲真實世界資料（RWD）市場分析

第10章 南美市場分析

第11章 公司簡介

公司簡介（公司概況、財務指標、主要產品組合、主要負責人、主要競爭對手、聯絡資訊和業務策略展望）

  • IQVIA Holding Inc.
  • IBM Corporation
  • Tempus Labs Inc.
  • Syneos Health Inc.
  • Evidera Inc.
  • Palantir Technologies Inc.
  • SAS Institute
  • Flatiron Health
  • Optum Inc.
  • Cerner Corporation
  • 其他主要公司

第12章 附錄

簡介目錄
Product Code: AA08261923

The global real-world data (RWD) market is undergoing rapid expansion as pharmaceutical companies, healthcare providers, biotechnology firms, research organizations, and other healthcare stakeholders increasingly recognize the value of evidence generated from routine clinical practice. The market was valued at approximately USD 1.92 billion in 2025 and is projected to reach USD 7.31 billion by 2035, representing a compound annual growth rate (CAGR) of 14.30% during the 2026-2035 forecast period.

One of the most significant factors contributing to market expansion is the global shift toward precision medicine. Conventional treatment strategies often rely on broad patient populations, whereas precision medicine seeks to identify therapies and interventions that are better suited to the biological, genetic, clinical, and demographic characteristics of individual patients. Real-world data can provide researchers with extensive information about patient characteristics, treatment histories, disease progression, treatment responses, and clinical outcomes.

Noteworthy Market Developments

The global real-world data (RWD) market is characterized by strong competition among major healthcare information, analytics, technology, and clinical research companies. IQVIA, Flatiron Health, Optum, Syneos Health, and Oracle Cerner have established prominent positions.

IQVIA maintains a particularly strong position in the RWD market through its extensive global healthcare information ecosystem and advanced analytics capabilities. Flatiron Health has established a specialized position within the RWD market through its strong focus on oncology.

Optum has developed another major competitive advantage through its extensive healthcare and payer ecosystem. Syneos Health differentiates itself by combining real-world evidence capabilities with extensive experience in clinical research and contract research services. Oracle Cerner brings a different competitive advantage through its extensive presence within hospital and healthcare information infrastructure.

Core Growth Driver

Rising clinical trial costs and high failure rates are major factors driving the growth of the real-world data (RWD) market. Pharmaceutical and biotechnology companies face substantial financial and operational challenges when developing new therapies, with significant investments required across discovery, preclinical research, clinical development, regulatory submissions, and commercialization. The risk of failure remains considerable, particularly during clinical-stage development, where unsuccessful trials can result in the loss of years of research and hundreds of millions of dollars in development expenditure. As a result, life science companies are increasingly turning to real-world data to improve decision-making, reduce avoidable development risks, and increase the efficiency of clinical research programs.

Emerging Opportunity Trends

AI- and NLP-powered data curation is emerging as a significant opportunity for growth in the real-world data (RWD) market. Healthcare organizations, pharmaceutical companies, biotechnology firms, and research institutions generate enormous volumes of information in both structured and unstructured formats. While structured data such as laboratory values, medication codes, diagnoses, and procedure records can be readily incorporated into databases, a substantial amount of clinically valuable information remains embedded within unstructured physician notes, pathology reports, discharge summaries, radiology reports, and other narrative documentation. Advanced artificial intelligence and natural language processing (NLP) technologies are increasingly being deployed to convert this complex narrative information into standardized and analysis-ready datasets.

Barriers to Optimization

Data privacy and regulatory liabilities represent a significant challenge that may restrain the growth of the global real-world data (RWD) market. The increasing use of electronic health records, claims databases, patient registries, genomic information, and other healthcare datasets has created substantial opportunities for research and analytics, but it has also increased the complexity of protecting sensitive patient information. Healthcare data can contain highly confidential clinical, demographic, genetic, and treatment-related information, making organizations particularly vulnerable to privacy breaches, unauthorized access, inappropriate data sharing, and regulatory violations. As the volume of healthcare information used for research and commercial purposes continues to expand, maintaining strong privacy and governance controls is becoming increasingly critical.

Detailed Market Segmentation

By component, data assets and databases occupy a leading position in the global real-world data (RWD) market, supported by the rapidly increasing demand for high-quality, longitudinal, and AI-ready healthcare datasets. Pharmaceutical companies, biotechnology firms, healthcare providers, research organizations, and technology companies increasingly recognize that the value of advanced analytics and artificial intelligence depends heavily on the quality, completeness, accessibility, and structure of the underlying data. As organizations seek to develop more sophisticated clinical, commercial, and research applications, demand for comprehensive databases capable of supporting longitudinal patient analysis has increased substantially.

By data source, electronic health records (EHRs) represent the leading source within the global real-world data (RWD) market. Their dominant position is supported by the depth, breadth, and clinical detail of information captured throughout routine patient care. Unlike data sources that primarily focus on financial or administrative transactions, EHR systems can contain longitudinal information covering diagnoses, clinical observations, laboratory results, medications, procedures, treatment histories, and other patient-level variables. This comprehensive view enables researchers and pharmaceutical companies to follow patient trajectories over time and generate detailed insights into how diseases progress and how treatments perform under real-world conditions.

By application, drug development and clinical research represent the leading segment of the global real-world data (RWD) market, accounting for approximately 55% of the overall market share. Its dominant position reflects the growing use of real-world data to supplement conventional clinical trial evidence, improve research efficiency, identify suitable patient populations, and support evidence generation throughout the pharmaceutical development lifecycle. Pharmaceutical companies and research organizations are increasingly incorporating information from electronic health records, claims databases, patient registries, disease-specific databases, and other healthcare sources into clinical development strategies. The expanding availability of large-scale healthcare datasets has consequently positioned RWD as an important component of modern drug research.

By end user, pharmaceutical companies represent the leading segment of the global real-world data (RWD) market, accounting for approximately 34% of the market share. Their dominant position is primarily driven by the growing need to use evidence generated from routine clinical practice to support drug development, regulatory submissions, market access, safety monitoring, and commercial decision-making. Pharmaceutical companies increasingly rely on real-world data from electronic health records, insurance claims, patient registries, clinical databases, pharmacy records, and other healthcare sources to complement evidence generated through traditional clinical trials. The increasing availability of large and diverse healthcare datasets has therefore made RWD an important strategic resource throughout the pharmaceutical product lifecycle.

Segment Breakdown

By Component

  • Data Assets & Databases
  • Analytics & Technology Platforms
  • Services
  • Data Aggregation Services
  • Data Curation & Integration Services
  • RWE Generation Services
  • Consulting Services
  • Regulatory & Market Access Support

By Data Source

  • Electronic Health Records (EHRs)
  • Claims & Billing Data
  • Patient Registries
  • Pharmacy Data
  • Genomics & Omics Data
  • Wearable & Remote Monitoring Data
  • Patient-Generated Health Data
  • Laboratory Data
  • Imaging Data

By Deployment Model

  • Cloud-Based
  • On-Premise
  • Hybrid

By Application

  • Drug Development & Clinical Research
  • Pharmacovigilance & Drug Safety
  • Regulatory Decision Support
  • Market Access & Reimbursement
  • Precision Medicine
  • Clinical Outcome Assessment
  • Healthcare Operations & Population Health Management
  • Health Economics & Outcomes Research (HEOR)

By Therapeutic Area

  • Oncology
  • Cardiology
  • Neurology
  • Immunology
  • Rare Diseases
  • Metabolic Disorders
  • Infectious Diseases
  • Respiratory Diseases
  • Others

By End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Healthcare Providers
  • Payers & Insurance Organizations
  • Government & Regulatory Agencies
  • Academic & Research Institutes

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America led the global market in 2025, accounting for approximately 44% of the total market share. The region's strong position was supported by its advanced healthcare infrastructure, high levels of digital technology adoption, significant investments in health information systems, and growing emphasis on interoperability across healthcare organizations.
  • The United States has played a central role in accelerating healthcare technology integration through the widespread adoption of electronic health records and standardized digital health information systems. Major hospitals and healthcare networks have invested heavily in interoperable platforms designed to allow patient information to be exchanged across different providers, facilities, laboratories, pharmacies, and other healthcare stakeholders.
  • Canada has also made an important contribution to North America's market position through the continued expansion of digital health infrastructure across its provincial healthcare systems. Canadian healthcare organizations have increasingly adopted electronic medical records, digital health platforms, and centralized or interconnected registries to improve access to patient information and support more coordinated care.

Leading Market Participants

  • IQVIA Holding Inc.
  • IBM Corporation
  • Tempus Labs Inc.
  • Syneos Health Inc.
  • Evidera Inc.
  • Palantir Technologies Inc.
  • SAS Institute
  • Flatiron Health
  • Optum Inc.
  • Cerner Corporation
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary

  • 1.1. Global Real-World Data (RWD) Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary Sources
    • 2.4.2. Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary Sources
    • 2.5.2. Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Real-World Data (RWD) Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Data-Source (EHR, Claims, Registry, Pharmacy, Wearable) Originators
    • 3.1.2. Data Aggregation, Curation, Tokenization & De-Identification Providers
    • 3.1.3. Analytics & Technology Platform (RWE Generation) Developers
    • 3.1.4. Consulting, Regulatory & Market-Access Support Partners
    • 3.1.5. End Users (Pharma, Biotech, CROs, Providers, Payers, Government, Academia)
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Real-World Data (RWD) & Real-World Evidence (RWE) Industry
    • 3.2.2. RWD/RWE Supplementing RCTs for Regulatory Decisions, External Control Arms & Label Expansion
    • 3.2.3. EHR Interoperability, Tokenization, AI-Ready Genomic-Clinical Linked Datasets & Privacy-Governed Monetization
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of New Entrants
    • 3.4.4. Threat of Substitutes
    • 3.4.5. Intensity of Rivalry
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Component

Chapter 4. Global Real-World Data (RWD) Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Real-World Data (RWD) Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Component
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Data Assets & Databases
        • 5.2.1.1.2. Analytics & Technology Platforms
        • 5.2.1.1.3. Services
        • 5.2.1.1.4. Data Aggregation Services
        • 5.2.1.1.5. Data Curation & Integration Services
        • 5.2.1.1.6. RWE Generation Services
        • 5.2.1.1.7. Consulting Services
        • 5.2.1.1.8. Regulatory & Market Access Support
    • 5.2.2. By Data Source
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Electronic Health Records (EHRs)
        • 5.2.2.1.2. Claims & Billing Data
        • 5.2.2.1.3. Patient Registries
        • 5.2.2.1.4. Pharmacy Data
        • 5.2.2.1.5. Genomics & Omics Data
        • 5.2.2.1.6. Wearable & Remote Monitoring Data
        • 5.2.2.1.7. Patient-Generated Health Data
        • 5.2.2.1.8. Laboratory Data
        • 5.2.2.1.9. Imaging Data
    • 5.2.3. By Deployment Model
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Cloud-Based
        • 5.2.3.1.2. On-Premise
        • 5.2.3.1.3. Hybrid
    • 5.2.4. By Application
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Drug Development & Clinical Research
        • 5.2.4.1.2. Pharmacovigilance & Drug Safety
        • 5.2.4.1.3. Regulatory Decision Support
        • 5.2.4.1.4. Market Access & Reimbursement
        • 5.2.4.1.5. Precision Medicine
        • 5.2.4.1.6. Clinical Outcome Assessment
        • 5.2.4.1.7. Healthcare Operations & Population Health Management
        • 5.2.4.1.8. Health Economics & Outcomes Research (HEOR)
    • 5.2.5. By Therapeutic Area
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Oncology
        • 5.2.5.1.2. Cardiology
        • 5.2.5.1.3. Neurology
        • 5.2.5.1.4. Immunology
        • 5.2.5.1.5. Rare Diseases
        • 5.2.5.1.6. Metabolic Disorders
        • 5.2.5.1.7. Infectious Diseases
        • 5.2.5.1.8. Respiratory Diseases
        • 5.2.5.1.9. Others
    • 5.2.6. By End User
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. Pharmaceutical Companies
        • 5.2.6.1.2. Biotechnology Companies
        • 5.2.6.1.3. Contract Research Organizations (CROs)
        • 5.2.6.1.4. Healthcare Providers
        • 5.2.6.1.5. Payers & Insurance Organizations
        • 5.2.6.1.6. Government & Regulatory Agencies
        • 5.2.6.1.7. Academic & Research Institutes
    • 5.2.7. By Region
      • 5.2.7.1. Key Insights
        • 5.2.7.1.1. North America
          • 5.2.7.1.1.1. The U.S.
          • 5.2.7.1.1.2. Canada
          • 5.2.7.1.1.3. Mexico
        • 5.2.7.1.2. Europe
          • 5.2.7.1.2.1. Western Europe
            • 5.2.7.1.2.1.1. The UK
            • 5.2.7.1.2.1.2. Germany
            • 5.2.7.1.2.1.3. France
            • 5.2.7.1.2.1.4. Italy
            • 5.2.7.1.2.1.5. Spain
            • 5.2.7.1.2.1.6. Rest of Western Europe
          • 5.2.7.1.2.2. Eastern Europe
            • 5.2.7.1.2.2.1. Poland
            • 5.2.7.1.2.2.2. Russia
            • 5.2.7.1.2.2.3. Rest of Eastern Europe
        • 5.2.7.1.3. Asia Pacific
          • 5.2.7.1.3.1. China
          • 5.2.7.1.3.2. India
          • 5.2.7.1.3.3. Japan
          • 5.2.7.1.3.4. Australia & New Zealand
          • 5.2.7.1.3.5. South Korea
          • 5.2.7.1.3.6. ASEAN
          • 5.2.7.1.3.7. Rest of Asia Pacific
        • 5.2.7.1.4. Middle East & Africa (MEA)
          • 5.2.7.1.4.1. Saudi Arabia
          • 5.2.7.1.4.2. South Africa
          • 5.2.7.1.4.3. UAE
          • 5.2.7.1.4.4. Rest of MEA
        • 5.2.7.1.5. South America
          • 5.2.7.1.5.1. Argentina
          • 5.2.7.1.5.2. Brazil
          • 5.2.7.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Component
      • 6.2.1.2. By Data Source
      • 6.2.1.3. By Deployment Model
      • 6.2.1.4. By Application
      • 6.2.1.5. By Therapeutic Area
      • 6.2.1.6. By End User
      • 6.2.1.7. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Component
      • 7.2.1.2. By Data Source
      • 7.2.1.3. By Deployment Model
      • 7.2.1.4. By Application
      • 7.2.1.5. By Therapeutic Area
      • 7.2.1.6. By End User
      • 7.2.1.7. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Component
      • 8.2.1.2. By Data Source
      • 8.2.1.3. By Deployment Model
      • 8.2.1.4. By Application
      • 8.2.1.5. By Therapeutic Area
      • 8.2.1.6. By End User
      • 8.2.1.7. By Country

Chapter 9. Middle East & Africa (MEA) Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Component
      • 9.2.1.2. By Data Source
      • 9.2.1.3. By Deployment Model
      • 9.2.1.4. By Application
      • 9.2.1.5. By Therapeutic Area
      • 9.2.1.6. By End User
      • 9.2.1.7. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Component
      • 10.2.1.2. By Data Source
      • 10.2.1.3. By Deployment Model
      • 10.2.1.4. By Application
      • 10.2.1.5. By Therapeutic Area
      • 10.2.1.6. By End User
      • 10.2.1.7. By Country

Chapter 11. Company Profile

Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. IQVIA Holding Inc.
  • 11.2. IBM Corporation
  • 11.3. Tempus Labs Inc.
  • 11.4. Syneos Health Inc.
  • 11.5. Evidera Inc.
  • 11.6. Palantir Technologies Inc.
  • 11.7. SAS Institute
  • 11.8. Flatiron Health
  • 11.9. Optum Inc.
  • 11.10. Cerner Corporation
  • 11.11. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators